Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,648,076
  • Shares Outstanding, K 306,659
  • Annual Sales, $ 967,780 K
  • Annual Income, $ 321,010 K
  • 60-Month Beta 1.54
  • Price/Sales 7.66
  • Price/Cash Flow 22.31
  • Price/Book 4.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.12
  • Number of Estimates 4
  • High Estimate 0.18
  • Low Estimate 0.08
  • Prior Year 0.25
  • Growth Rate Est. (year over year) -52.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.61 +15.41%
on 06/11/20
25.43 -1.93%
on 07/10/20
+1.81 (+7.83%)
since 06/10/20
3-Month
17.54 +42.19%
on 04/13/20
27.80 -10.29%
on 05/12/20
+6.92 (+38.40%)
since 04/09/20
52-Week
13.67 +82.44%
on 03/17/20
27.80 -10.29%
on 05/12/20
+4.00 (+19.10%)
since 07/10/19

Most Recent Stories

More News
Exelixis Inc Set to Possibly Pullback After Yesterday's Rally of 2.15%

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $24.26 to a high of $25.43. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $24.12...

EXEL : 24.94 (+3.14%)
Global Liver Cancer Therapeutics Market By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Region, Forecast & Opportunities, 2025

, /PRNewswire/ --Read the full report: As on date of publishing, this report will capture the impact assessment of COVID-19 on this market and the same will be considered in our market forecast model....

ARQL : 20.00 (+0.15%)
BAYRY : 17.9800 (+0.45%)
BMY : 57.43 (-1.17%)
CLSN : 3.58 (-2.72%)
ESALF : 80.0100 (+1.28%)
EXEL : 24.94 (+3.14%)
MRK : 76.73 (+0.05%)
NVS : 87.01 (-0.38%)
PFE : 33.83 (+1.11%)
Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer

--- CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche -

EXEL : 24.94 (+3.14%)
Exelixis (EXEL) in Focus: Stock Moves 7.6% Higher

Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

EXEL : 24.94 (+3.14%)
AXLA : 5.09 (-0.97%)
Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities...

EXEL : 24.94 (+3.14%)
Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer

--- CONTACT-01 is the first of three phase 3 pivotal trials that are part of a previously announced clinical collaboration with Roche -

EXEL : 24.94 (+3.14%)
Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EXEL : 24.94 (+3.14%)
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June

Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis' management team will participate in fireside chats at the following virtual investor conferences in June:

EXEL : 24.94 (+3.14%)
Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types

--- 27% objective response rate seen in immune checkpoint inhibitor-pretreated non-small cell lung cancer cohort 7 -

EXEL : 24.94 (+3.14%)
SmarTrend Watching for Potential Pullback in Shares of Exelixis Inc After 4.62% Gain

Exelixis Inc (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $25.67 to a high of $27.24. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high of $26.95...

EXEL : 24.94 (+3.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade EXEL with:

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Key Turning Points

2nd Resistance Point 26.05
1st Resistance Point 25.49
Last Price 24.94
1st Support Level 24.32
2nd Support Level 23.71

See More

52-Week High 27.80
Last Price 24.94
Fibonacci 61.8% 22.40
Fibonacci 50% 20.74
Fibonacci 38.2% 19.07
52-Week Low 13.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar